Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.53 |
| ▸ | PPARD | Q03181 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 5/20 | 0.53 |
| ▸ | F7 | P08709 | 4/20 | 0.53 |
| ▸ | F3 | P13726 | 4/20 | 0.53 |
| ▸ | TERT | O14746 | 3/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | FABP4 | P15090 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1271901 | 1.00 | PPARG (0.53) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL456745 | 1.00 | PPARG (0.53) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL1273217 | 0.91 | GPR84 (0.44) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| SCHEMBL5490197 | 0.91 | GPR84 (0.44) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| SCHEMBL45203 | 0.91 | GPR84 (0.44) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| SCHEMBL30413 | 0.91 | GPR84 (0.44) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| SCHEMBL253962 | 0.91 | GPR84 (0.44) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| SCHEMBL5495040 | 0.91 | GPR84 (0.44) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| SCHEMBL5395520 | 0.89 | AKR1B1 (0.42) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| SCHEMBL786356 | 0.84 | EPHX2 (0.47) | PPARGPPARDPPARAF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180940-A1 | MPLA COMPOSITIONS AND METHODS OF USE | REVELATION BIOSCIENCES, INC. | 2024-06-06 | — | — | US | claimed |
| WO-2024091615-A1 | METHODS OF ADJUVANT TREATMENT FOR ALLERGY IMMUNOTHERAPY | REVELATION BOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | claimed |
| EP-4346766-A1 | METHODS OF TREATING OR PREVENTING ALLERGIES AND CHRONIC NASAL CONGESTION | Revelation Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4346896-A1 | MPLA COMPOSITIONS AND METHODS OF USE | Revelation Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| US-20230321251-A1 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2023-10-12 | — | — | US | claimed |
| EP-4209229-A1 | LIPOSOME PREPARATION CONTAINING ANTIBACTERIAL DRUG | OSAKA UNIVERSITY (JP) | 2023-07-12 | — | — | EP | claimed |
| WO-2022251444-A1 | MPLA COMPOSITIONS AND METHODS OF USE | REVELATION BIOSCIENCES, INC. (US) | 2022-12-01 | — | — | WO | claimed |
| EP-3634470-A1 | GLUCOSE SENSITIVE COMPOSITIONS FOR DRUG DELIVERY | North Carolina State University (US) | 2020-04-15 | — | — | EP | claimed |
| US-20200085743-A1 | GLUCOSE SENSITIVE COMPOSITIONS FOR DRUG DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-03-19 | — | — | US | claimed |
| WO-2018223114-A1 | GLUCOSE SENSITIVE COMPOSITIONS FOR DRUG DELIVERY | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-12-06 | — | — | WO | claimed |
| US-20240180940-A1 | MPLA COMPOSITIONS AND METHODS OF USE | REVELATION BIOSCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| WO-2024091615-A1 | METHODS OF ADJUVANT TREATMENT FOR ALLERGY IMMUNOTHERAPY | REVELATION BOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4346896-A1 | MPLA COMPOSITIONS AND METHODS OF USE | Revelation Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4346766-A1 | METHODS OF TREATING OR PREVENTING ALLERGIES AND CHRONIC NASAL CONGESTION | Revelation Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240082359-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2011038068-A1 | METHODS FOR THE PREPARATION OF LIPOSOMES | FORMATECH, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20110070295-A1 | METHODS FOR THE PREPARATION OF LIPOSOMES COMPRISING DOCETAXEL | JAVERI, INDU | 2011-03-24 | — | — | US | disclosed |
| US-20110070293-A1 | Methods for the Preparation of Liposomes Comprising Docetaxel | JAVERI, INDU | 2011-03-24 | — | — | US | disclosed |
| US-20110070292-A1 | Methods For The Preparation Of Liposomes | CURIRX INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070294-A1 | Methods for the Administration of Drugs Using Liposomes | JAVERI, INDU | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321251-A1 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | LIPA, LIPG, LIPC | PPARG 3244/4885PPARD 3225/4885PPARA 1392/4885 |
| US-20240082359-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | PPARG 623/4885PPARD 1525/4885PPARA 1102/4885 |
| US-20200085743-A1 | GLUCOSE SENSITIVE COMPOSITIONS FOR DRUG DELIVERY | SLC2A1, SLC2A8, SLC2A4 | PPARG 3024/4885PPARD 4639/4885PPARA 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.